Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Other Non-Current Assets (2021 - 2025)

Historic Other Non-Current Assets for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to $8.2 million.

  • Coeptis Therapeutics Holdings' Other Non-Current Assets rose 791.65% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 791.65%. This contributed to the annual value of $7.8 million for FY2024, which is 17924.24% up from last year.
  • Latest data reveals that Coeptis Therapeutics Holdings reported Other Non-Current Assets of $8.2 million as of Q3 2025, which was up 791.65% from $8.5 million recorded in Q2 2025.
  • Over the past 5 years, Coeptis Therapeutics Holdings' Other Non-Current Assets peaked at $8.8 million during Q1 2025, and registered a low of $2.5 million during Q1 2024.
  • Its 5-year average for Other Non-Current Assets is $5.4 million, with a median of $4.3 million in 2021.
  • Per our database at Business Quant, Coeptis Therapeutics Holdings' Other Non-Current Assets crashed by 3148.89% in 2024 and then surged by 25118.71% in 2025.
  • Quarter analysis of 5 years shows Coeptis Therapeutics Holdings' Other Non-Current Assets stood at $4.6 million in 2021, then fell by 13.36% to $4.0 million in 2022, then dropped by 29.06% to $2.8 million in 2023, then soared by 179.24% to $7.8 million in 2024, then grew by 4.25% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, $8.5 million for Q2 2025, and $8.8 million during Q1 2025.